[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606809":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":128,"collaborators":19,"id":132,"slug":19,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":133,"sex":138,"minAge":139,"maxAge":19,"enrollmentInfo":140,"targetDuration":19,"studyType":143,"phases":144,"briefSummary":146,"conditions":147,"keywords":19,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"St. Antonius Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study arm","EXPERIMENTAL","Participants will not undergo immediate prostate biopsy but will be monitored with PSA testing every six months and prostate MRI annually.",[13],"Other: PSA and MRI-monitoring",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"PSA and MRI-monitoring","Men with PI-RADS 3 or 4 lesions and a PSA density ≤ 0.15 ng\u002FmL² are actively monitored with PSA testing every six months and MRI annually, instead of undergoing immediate prostate biopsy.",[9],null,[21,41,56,70,80,94,109],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Treant","RECRUITING","Emmen","Drenthe","7824AA","Netherlands","NL",{"type":30,"coordinates":31},"Point",[32,33],6.90694,52.77917,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":19,"email":40},"Luc A.J. Roelofs, MD, PhD","CONTACT","+310881290147","l.roelofs@treant.nl",{"facility":42,"status":23,"city":43,"state":44,"zip":45,"country":27,"countryCode":28,"cosmosGeoPoint":46,"geoPoint":50,"contacts":51},"Andros Clinics","Arnhem","Gelderland","6842 CV",{"type":30,"coordinates":47},[48,49],5.91111,51.98,{"lat":49,"lon":48},[52],{"name":53,"role":38,"phone":54,"phoneExt":19,"email":55},"Paul J.M. Kil, MD PhD","026 389 1753","p.kil@andros.nl",{"facility":57,"status":23,"city":58,"state":44,"zip":59,"country":27,"countryCode":28,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Radboud University Medical Centre","Nijmegen","6525 GA",{"type":30,"coordinates":61},[62,63],5.85278,51.8425,{"lat":63,"lon":62},[66],{"name":67,"role":38,"phone":68,"phoneExt":19,"email":69},"Toine G van der Heijden, MD PhD","024361 38 03","toine.vanderheijden@radboudumc.nl",{"facility":71,"status":23,"city":58,"state":44,"zip":19,"country":27,"countryCode":28,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Canisius Wilhelmina Hospital",{"type":30,"coordinates":73},[62,63],{"lat":63,"lon":62},[76],{"name":77,"role":38,"phone":78,"phoneExt":19,"email":79},"Rik M Somford, MD PhD","024 365 8255","r.somford@cwz.nl",{"facility":81,"status":23,"city":82,"state":83,"zip":19,"country":27,"countryCode":28,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Antoni van Leeuwenhoek Hospital","Amsterdam","North Holland",{"type":30,"coordinates":85},[86,87],4.88969,52.37403,{"lat":87,"lon":86},[90],{"name":91,"role":38,"phone":92,"phoneExt":19,"email":93},"Laura S Mertens, MD PhD","0205129111","l.mertens@nki.nl",{"facility":95,"status":96,"city":97,"state":98,"zip":19,"country":27,"countryCode":28,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Maasstad Hospital","NOT_YET_RECRUITING","Rotterdam","South Holland",{"type":30,"coordinates":100},[101,102],4.47917,51.9225,{"lat":102,"lon":101},[105],{"name":106,"role":38,"phone":107,"phoneExt":19,"email":108},"Roderick C.N. van den Bergh, MD PhD","0102912265","BerghR@maasstadziekenhuis.nl",{"facility":110,"status":23,"city":111,"state":112,"zip":113,"country":27,"countryCode":28,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"St Antonius Hospital","Nieuwegein","Utrecht","3435 CM",{"type":30,"coordinates":115},[116,117],5.08056,52.02917,{"lat":117,"lon":116},[120,124],{"name":121,"role":38,"phone":122,"phoneExt":19,"email":123},"Vera Sweere, MD","0031612138028","v.sweere@antoniusziekenhuis.nl",{"name":125,"role":38,"phone":126,"phoneExt":19,"email":127},"Harm H.E. Van Melick, MD PhD","00316683201444","h.van.melick@antoniusziekenhuis.nl",{"type":129,"investigatorFullName":130,"investigatorTitle":131,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Harm H.E. Van Melick","MD PhD","100606809",false,"NCT07180381","Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer","SPROUT","Inclusion Criteria:\n\n* Life expectancy \\> 10 years\n* initial PSA \\\u003C 20 ng\u002Fml\n* No signs of extracapsular disease on digital rectal examination\n* Intermediate-risk category for suspicion of prostate cancer determined by MRI results and PSA density (PSAD): PI-RADS 3 or PI-RADS 4 with PSAD =\\\u003C 0.15\n* Mentally competent and able to comprehend the potential benefits and burdens of the study\n* Willing to undergo the follow-up protocol for a maximum of four years\n* written and signed informed consent\n\nExclusion Criteria:\n\n* Men who have previously undergone a prostate biopsy\n* Men who have a prior PCa diagnosis\n* using any (anti-)hormonal therapy, including 5-alpha-reductase inhibitors\n* Proven germline mutation for PCa (for example: BRCA1; BRCA2)\n* Secondary malignancy, besides basal cell carcinoma of the skin, for which the potential participant is receiving active treatment at the time of inclusion.\n* severe claustrofobia or other conditions that make (repeat) MRI unsuitable (e.g., metal implants, pacemakers)","MALE","18 Years",{"count":141,"type":142},503,"ESTIMATED","INTERVENTIONAL",[145],"NA","The goal of this clinical trial is to evaluate the safety and effectiveness of a novel diagnostic strategy for prostate cancer, in which men with a moderate risk of prostate cancer are monitored using PSA and MRI instead of immediate biopsy,.\n\nThe main questions it aims to answer are:\n\n* Is it safe to delay biopsy, making sure that clinical significant prostate cancers are not often missed?\n* Does it reduce unnecessary biopsies and overtreatment?",[148],"Prostate Cancer","2025-11-26",{"date":151,"type":152},"2025-12-04","ACTUAL",{"date":154,"type":152},"2025-05-14",{"date":156,"type":142},"2031-01",{"name":5,"class":6},7]